Here below are the publications (2) participated by Silke Gillessen Sommer using the term string limitations (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).
Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4-6
European Urology, ottobre 2023

2) A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research
European Urology Oncology, 7 gennaio 2021
Silke Gillessen Sommer
is Head of Research Programs [Rif. 20700]
at Istituto Oncologico Svizzera Italiana (IOSI) (Rif. IOSI)
Via Gallino 12 (ex Via Ospedale) 6500 Bellinzona
Silke Gillessen Sommer
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents (Rif. 36000 202407)